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ABSTRACT
Background: Globally, radon is the leading risk factor for lung cancer in never-smokers (LCINS). In this
study, we systematically reviewed and meta-analysed the evidence of the risk of LCINS associated with
residential radon exposure.
Methods: Medline and Embase databases were searched using predefined inclusion and exclusion criteria
to identify relevant studies published from 1 January 1990 to 5 March 2020 focused on never-smokers. We
identified four pooled collaborative studies (incorporating data from 24 case–control studies), one case–
control study and one cohort study for systematic review. Meta-analysis was performed on the results of
the four pooled studies due to different measures of effect and outcome reported in the cohort study and
insufficient information reported for the case–control study. In a post hoc analysis, the corresponding risk
for ever-smokers was also examined.
Results: Risk estimates of lung cancer from residential radon exposure were pooled in the meta-analysis
for 2341 never-smoker cases, 8967 never-smoker controls, 9937 ever-smoker cases and 12463 ever-smoker
controls. Adjusted excess relative risks (aERRs) per 100 Bq·m−3 of radon level were 0.15 (95% CI 0.06–
0.25) for never-smokers and 0.09 (95% CI 0.03–0.16) for ever-smokers, and the difference between them
was statistically insignificant (p=0.32). The aERR per 100 Bq·m−3was higher for men (0.46; 95% CI 0.15–
0.76) than for women (0.09; 95% CI −0.02–0.20) among never-smokers (p=0.027).
Conclusion: This study provided quantified risk estimates for lung cancer from residential radon exposure
among both never-smokers and ever-smokers. Among never-smokers in radon-prone areas, men were at
higher risk of lung cancer than women.
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Lung cancer has long been the most commonly diagnosed cancer and the leading cause of cancer-related
deaths globally [1]. Although tobacco smoking is responsible for the great majority of lung cancers, 15 to
25% of cases occur in lifelong never-smokers [1–3] (“never-smokers” are defined as individuals who have
smoked <100 cigarettes in their lifetime according to the International Consortium for Health Outcomes
Measurement [4]). Lung cancer in never-smokers (LCINS) has been recognised as a distinct disease entity
from that in ever-smokers [2, 3, 5–8], and its significant impact has been indicated by being ranked in
2000 as the seventh most common cause of cancer death worldwide [2, 9, 10]. Numerous risk factors have
been suggested for the development of LCINS, including exposure to radon, asbestos, environmental
tobacco smoke, air pollution, heavy metals, lifestyle factors, female hormonal factors, human
papillomavirus infection and inherited genetic susceptibility [7, 11–13]. Radon was classified as a Group 1
carcinogen for lung cancer by the International Agency for Research on Cancer (IARC) [14]. Also, based on
substantial epidemiological evidence showing a strong and consistent dose–response relationship of increased
lung cancer risk with high-level occupational radon exposure amongst underground miners [15–17], radon
exposure has been identified as the second strongest risk factor for lung cancer only after smoking, and is the
leading risk factor for LCINS worldwide [18, 19]. However, the risk estimate of lung cancer from exposure to
residential radon in the general population remains unclear.
Radon is a naturally occurring radioactive noble gas present throughout the earth’s crust. As a chemically
inert gas, it can readily diffuse through rocks and soil into any air space and accumulate in enclosed areas
or unventilated environments [20]. One of its isotopes closely linked to lung cancer, Radon-222, is a
transient product of the uranium-238 decay chain [21], and is the greatest source of radiation for
humans [22]. As Radon has a half-life of 3.82 days, when it is inhaled, most of the Radon is exhaled
before it undergoes substantial decay. However, the decay products or radon progenies adhere to the
airways of the lungs, where they are thought to continue to emit radioactive alpha particles to induce
carcinogenesis and potentially culminate in lung cancer. The radiation received by humans via radon
progeny is higher than that via radon-222 itself, but it is directly proportional to radon-222 exposure [23].
In extrapolating the risk of occupational radon exposure among miners to residential radon exposure in
the general population, there are several limitations: 1) the health effects of residential radon are more
difficult to evaluate due to the much lower radon concentration in residential environments than that in
mines (about 100 times lower); 2) the air composition in mines contains some other carcinogens (such as
arsenic and various dusts) that are not commonly found in residential dwellings; and 3) the characteristics
of the exposed populations are different, as miners are usually young men, while both sexes of all ages can
be exposed to residential radon [24].
Since 1990, numerous case–control studies have been conducted in both high- and low-radon areas in
Europe, North America and China to assess the excess risks of lung cancer attributable to residential
radon exposure [25–45]. Due to the relatively small sample sizes of these case–control studies, large pooled
collaborative studies [46–52] and several meta-analyses [53–58] were conducted, aiming to acquire similar
statistical power as the epidemiologic studies of underground miners [59], as well as to provide a
comparison of the pooled risk estimates with extrapolations from the miner-based risk models [49]. While
the pooled collaborative studies have shown significant positive associations between residential radon
exposure and lung cancer risk to varying degrees, all but one pooled study [52] assessed this association in
populations of both ever-smokers and never-smokers. To establish a clear link between radon and LCINS,
it is important to focus on studies with exclusive or subgroup analyses of never-smokers, rather than
extrapolating excess risks among smokers to LCINS given the residual confounding by smoking and other
factors. We therefore undertook a systematic review and meta-analysis to examine and quantify the
association between residential radon exposure and lung cancer risk among never-smokers.
Methods
Protocol and registration
The conduct and reporting of this systematic review and meta-analysis adhered to the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) statement checklist [60] (supplementary table
1), and has been registered at PROSPERO with identifier number CRD42020154551.
Databases and search methods
Medline and Embase databases were initially searched for eligible articles published from 1990 onwards by
combining text terms and database specific subject headings for “lung cancer” and “radon” in November
2017 (supplementary table 2). Two more searches were then run in October 2019 and March 2020 and the
search results were updated to 5 March 2020 (supplementary table 3).
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Study eligibility criteria
The PICO (population, intervention, comparator and outcome) framework was adopted in our search
strategy, and studies were selected based on pre-defined inclusion and exclusion criteria which are
summarised in table 1. The population was never-smokers. The exposure of interest was indoor or
residential radon exposure, and the comparator was no or low radon exposure. The outcome was lung
cancer diagnosis or death. Published articles were included if they reported full or subgroup analyses of
the association between residential radon exposure and LCINS. A more detailed account of the application
of these criteria is provided in the Technical Appendix in the Supplementary material.
Study selection and data extraction
Titles and abstracts of citations identified by the database searches were examined by one reviewer
(E. Cheng) and clearly irrelevant articles were excluded. The full texts of the potentially relevant articles
were retrieved and evaluated for inclusion by one reviewer (E. Cheng); where uncertainties arose a second
reviewer (S. Hughes) was consulted. The reasons for excluding retrieved articles were documented.
Relevant pre-specified study characteristics relating to country/region of study, study design and
population, sex and population source, number of cases and controls, study period, exposure measurement
and results were extracted from the included articles by one reviewer (E. Cheng) and cross-checked by a
second reviewer (S. Hughes). Differences were resolved by discussion and/or advice from a third reviewer
(X.Q. Yu).
Assessment of study quality
The quality of the included studies was assessed independently by two reviewers (E. Cheng and X.Q. Yu).
The ROBIS tool [61] was used to assess the risk of bias (ROB) for the pooled collaborative studies, and
items were scored as low, high or unknown/unclear concern for ROB. Adaptions of the Newcastle–Ottawa
Scale developed to assess the ROB for epidemiological cohort studies and case–control studies [62] were
used to assess the cohort and case–control studies, and items were scored as low, moderate or high ROB.
Post hoc analysis for ever-smokers
As a post hoc analysis using relevant data from the included studies, we also conducted a meta-analysis to
examine and quantify the association between residential radon exposure and lung cancer risk among
ever-smokers in order to examine the role of personal smoking as an effect modifier.
Data extraction and management
For the meta-analysis, two reviewers (E. Cheng and S. Egger) extracted effect estimates and standard errors
for never-smokers and categories of ever-smokers (i.e. ever-smoker; or current-smoker and ex-smoker; or
TABLE 1 Inclusion and exclusion criteria for screening articles
Domain Inclusion criteria Exclusion criteria
Study type/design Pooled data analysis of cohort or case–
control studies
Ecological study case series
Meta-analysis of cohort or case–control
studies




Study population Never-smokers (<100 cigarettes in lifetime)
Exposure Indoor or residential radon exposure Mining radon exposure
Comparator No or lower radon exposure
Outcome Lung cancer diagnosis or death
Time of publication Published from 1 January 1990 to 5 March
2020
Published before 1990




Language English Language other than English
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ever-smoker with lifetime exposure divided into tertiles) in each study with discrepancies resolved by
consensus or adjudication from another reviewer (X.Q. Yu).
Preferably, estimates of the adjusted excess relative risk (aERR) per 100 Bq·m−3 were extracted if available.
The common confounders included in the adjustment were age, sex, education, occupations with high risk
of lung cancer and exposure to environmental tobacco smoke. Stata 14 was used for statistical analyses.
A full account of data extraction and management is provided in the Technical Appendix in the
supplementary material.
Data synthesis
To pool estimates of aERRs per 100 Bq·m−3 for never-smokers and ever-smokers, we used methods
outlined by LITTLE et al. [63]. Briefly, the fixed-effect inverse variance weighted pooled aERRs for









where aERRi is the reported aERR estimate for the ith individual or collaborative study, and SD(aERRi) is






A random-effects approach was not used because of the necessity to include pooled estimates from
collaborative studies in our meta-analysis. Also, a measure of heterogeneity across the component studies
in the pooled analysis, which is needed for an analysis using random effects, was not reported and could
not be assessed.
We also used the above method to pool estimates of aERRs per 100 Bq·m−3 for never-smokers stratified by
sex based on the results of the two collaborative studies that provided this information [51, 52].
Sensitivity analysis
We performed sensitivity analyses in which the component effect estimates were pooled on the log(RR)
scale (instead of the ERR scale) using the standard generic inverse variance method. The rationale for the
statistical analyses is provided in the Technical Appendix in the supplementary material.
Results
Search results
A flowchart of the search process and inclusion/exclusion results is shown in figure 1. We identified 2453
articles through an initial literature search of which nine met the selection criteria and were included in
the systematic review. Of these nine articles, seven reported the findings from four pooled collaborative
analyses [46–52] of case–control data from a total of 24 studies [25–40, 42–45, 64–66] (one of them,
TOMASEK [26], was a cohort study re-analysed as a nested case–control study in a pooled collaborative
analysis), one was a cohort study [67] and one was a case–control study [68] that had not been included
in any of the pooled analyses (table 2). Only the cohort study [67] examined associations with death from
lung cancer, all the remaining studies examined associations with a diagnosis of lung cancer.
For diagnosis of lung cancer, a meta-analysis of the four pooled collaborative analyses was undertaken.
Results of the Spanish pooled studies reported by LORENZO-GONZALEZ et al. [52] were updated for our
analysis with unpublished data obtained from the lead investigators and the results reported in
BARROS-DIOS et al. [33] were excluded as they had already contributed to the pooled study of DARBY et al.
[48]. The meta-analysis did not include the cohort study [67] and the individual case–control study [68]
because: 1) the cohort study reported measures of effect (aIRR and aHR) that are incompatible with the
aERRs and aRRs used in the pooled case–control analyses; and 2) the case–control study did not report
standard errors or confidence intervals for the relevant effect estimates.
Overall, four collaborative studies (containing pooled estimates from 24 individual studies) contributed to
the meta-analysis for never-smokers. Of these four studies, three pooled collaborative studies (reporting
pooled estimates from 21 individual studies) and one individual study (BARROS-DIOS et al. [66]) from the
fourth pooled study contributed to the meta-analysis for ever-smokers. Data were pooled for 2341
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never-smoker cases, 8967 never-smoker controls, 9937 ever-smoker cases and 12463 ever-smoker controls
(in total, 12278 cases and 21430 controls).
Of the 24 individual studies included in the never-smoker meta-analysis, 15 (from two pooled studies [51, 52])
were eligible for inclusion in the sex-stratified meta-analyses. In this analysis, data were pooled separately
for 990 female never-smoker cases and 2898 female never-smoker controls, and 370 male never-smoker
cases and 3176 male never-smoker controls (in total, 1360 never-smoker cases and 6074 never-smoker
controls, representing 58% and 68% of the never-smoker cases and controls included in the overall
never-smoker pooled estimate, respectively).
Quality of included studies
The ROB for each of the included studies is shown in supplementary table 4. Overall, the pooled
collaborative studies were rated as having a low ROB, the cohort study [67] was rated as having a
moderate ROB and the case–control study [68] was rated as having a high ROB.
Results from the meta-analysis
To quantify the association between residential radon exposure and lung cancer risk, we demonstrated that
the aERRs per 100 Bq·m−3 were 0.15 (95% CI 0.06–0.25) for never-smokers, 0.09 (95% CI 0.03–0.16) for
Records identified through Medline and 
Embase database searching
(n=2453)
(After duplicates removed) 
Records screened
(n=1578)
Full-text articles assessed 
for eligibility
(n=98)
Articles included in 
systematic review
(n=9)
7 articles reporting 4 pooled 
data analyses with 24 studies# 
Case–control study (1)
Cohort study (1)
Articles included in 
meta-analysis
(n=7)
7 articles reporting 4 pooled 
data analyses with 24 studies# 
Full-text articles excluded (n=89)
  Narrative review/conference (16)
  Inappropriate study design (8)
  No analysis/subgroup for never-smokers (9)
  Smoking status not differentiated (4)
  Exposure not residential radon (6)
  Relevant data included in other publications (41)























FIGURE 1 Flowchart of the search process and results for studies looking at radon and lung cancer in
never-smokers. #: these 24 studies are unique individual studies included in the four pooled data analyses.
Accordingly, BARROS-DIOS et al. [33], which appears in two of the four pooled data analyses, is only counted once.
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TABLE 2 Summary of the studies included in systematic review and meta-analysis
First author
[ref.]








Cases Controls Cases Controls
DARBY[48]#¶
DARBY[51]#¶
Europe 1960–99 Pooled study M/F General+hospital Diagnosis 884 5418 6040 8252
OBERAIGNER[25] Austria 1970–92 C-C M/F General Diagnosis 22 41 159 127
TOMASEK[26] Czechia 1960–99 Cohort Kodak LR115 M/F General Death 28 295 143 417
AUVINEN [27] Finland 1986–92 C-C Alpha track M/F General Diagnosis 44 229 772 752
RUOSTEENOJA[28] Finland 1979–85 C-C Radon
dosimeter
M General Diagnosis 3 33 155 291
BAYSSON[29] France 1990–99 C-C Kodalpha LR115 M/F Hospital Diagnosis 44 344 521 797
KREUZER[30] Germany:
eastern





M/F General Diagnosis 89 653 1225 1433
BOCHICCHIO[32] Italy 1993–96 C-C Radon
dosimeter
M/F Hospital Diagnosis 28 102 355 291
BARROS-DIOS [33] Spain 1992–94 C-C Alpha track M/F General Diagnosis 12 94 144 133
PERSHAGEN[34] Sweden 1980–84 C-C Solid-state alpha
track
M/F General Diagnosis 175 1156 682 761
LAGARDE[35] Sweden 1978–95 C-C Radon
dosimeter
M/F General Diagnosis 258 487
PERSHAGEN[44] Sweden:
Stockholm
1983–87 C-C Alpha track F General+hospital Diagnosis 36 181 160 194
DARBY[36] England 1988–95 C-C Small passive
radon
M/F General+hospital Diagnosis 26 896 874 2062
KREWSKI[49]#¶
KREWSKI[50]#¶
North America 1982–97 Pooled study M/F General Diagnosis 659 2185 2930 2681
SCHOENBERG[37] USA: New Jersey 1982–84 C-C Alpha track F General Diagnosis 61 213 372 189
LETOURNEAU[38] Canada:
Winnipeg
1983–90 C-C CR-39 alpha
track
M/F General Diagnosis 24 224 509 498
ALAVANJA[39] USA: Missouri 1986–92 C-C Alpha track F General Diagnosis 377 983 161 200
ALAVANJA[45] USA: Missouri 1993–94 C-C CR-39
alpha-particle
F General Diagnosis 31 62 471 480
FIELD[40] USA: Iowa 1993–97 C-C Alpha track F General Diagnosis 56 414 357 200
SANDLER[65] USA:
Connecticut
1989–92 C-C Alpha track etch M/F General Diagnosis 54 78 718 735































Cases Controls Cases Controls
LUBIN[46]#¶
LUBIN[47]#¶
China 1985–98 Pooled study M/F General Diagnosis 322+ 708+ 706 1266
BLOT[42] China: Shenyang 1985–87 C-C Radon
dosimeter
F General Diagnosis 113 213 162 120
WANG[43] China: Gansu 1994–98 C-C Alpha track M/F General Diagnosis 209 495 544 1146
LORENZO-GONZALEZ
[52]#§
Spain: northwest 2003–13 Pooled study Alpha track M/F Hospital Diagnosis 476+ 656+ 261f 264f
BARROS-DIOS
[66]¶
Spain: Galicia 2004–08 C-C Alpha track M/F Hospital Diagnosis 47 220 261 264
TORRES-DURAN
[64]##
Spain: Galicia 2011–13 C-C Alpha track M/F Hospital Diagnosis 192 329
WILCOX[68]¶¶ USA: New
Jersey
1989–92 C-C Alpha track M/F General Diagnosis 40 116 521 513
TURNER[67]¶¶ USA 1982–88 Cohort Mean
county-level of
radon
M/F General Death 271 375087 2733 355286
Data are presented as n. LC: lung cancer; C-C: case–control study; M: male; F: female. #: these studies are included in the meta-analysis for never-smokers; ¶: these studies are
included in the meta-analysis for ever-smokers; +: unpublished data provided by original investigators; §: this study has been revised by its lead investigator to exclude the results of
BARROS-DIOS [33] which was included in the DARBY [48] pooled study; ƒ: data for ever-smokers extracted from BARROS-DIOS [66] which was not analysed in the pooled study; ##: this study has
been updated from July 2013 by its lead investigator to include more cases and controls in the LORENZO-GONZALEZ [52] pooling study; ¶¶: these studies are not included in the meta-analysis



















ever-smokers and 0.11 (95% CI 0.06–0.17) overall (figure 2). The aERR for never-smokers was not
significantly different from that for ever-smokers (p=0.32). Sensitivity analyses which combined
component effect estimates on the log(RR) scale using the standard generic inverse variance method
provided similar pooled effect estimates (but on the RR scale) (supplementary figure 1) and a similar
p-value for the difference between aRRs for never-smokers and ever-smokers (p=0.35).
We also found different effects of radon on lung cancer risk for never-smokers by sex: aERRs per
100 Bq·m−3 were 0.09 (95% CI −0.02–0.20) for women and 0.46 (95% CI 0.15–0.76) for men; and the
difference between them was significant (p=0.027) (figure 3). The results from the sensitivity analysis were
similar (supplementary figure 2).
For risk of death from lung cancer for never-smokers, TURNER et al. [67] reported an adjusted HR of 0.77
(95% CI 0.47–1.25) per 100 Bq·m−3 in mean county-level residential radon concentrations during a 6 year
follow-up.
Female
  DARBY [51]
  LORENZO-GONZÁLEZ [52]
Subtotal
Male
  DARBY [51]




































FIGURE 3 Adjusted excess relative risk (aERR) and 95% CI per100 Bq·m−3 (radon exposure) for diagnosis of
lung cancer in never-smokers stratified by sex. p=0.027 for difference between male and female aERRs.
Never-smokers
  DARBY [51]
  KREWSKI [49]
  LORENZO-GONZÁLEZ [52]
  LUBIN (China) [46]
Subtotal
Ever-smokers
  DARBY [51]
  KREWSKI [49]
  LORENZO-GONZÁLEZ# [52]
























































FIGURE 2 Adjusted excess relative risk (aERR) and 95% CI per 100 Bq·m−3 (radon exposure) for diagnosis of
lung cancer. #: BARROS-DIOS et al. [66] in this pooled study contributed to the “ever-smoker” meta-analysis.
p=0.32 for test of difference between aERRs for never-smokers and ever-smokers.
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Discussion
This is the first systematic review and meta-analysis to quantify the association between residential radon
exposure and lung cancer risk for lifelong never-smokers. As the population of never-smokers is increasing
due to effective tobacco control policies in most countries, the link between radon and LCINS clearly has
important implications, and our study was able to quantify this link. We found a 15% excess relative risk
of lung cancer for never-smokers when exposed to radon levels per 100 Bq·m−3. The excess risk of lung
cancer for ever-smokers was 9% per 100 Bq·m−3 radon exposure and this was not statistically significantly
different to that for never-smokers. The excess relative risks were 46% for men and 9% for women among
never-smokers, and the difference between them was significant (p=0.027).
When examining the association between radon exposure and lung cancer risk, population studies
conducted exclusively on never-smokers are recommended to reduce the potential residual confounding
effects of smoking, as the impact of smoking on lung cancer risk is far stronger than that from residential
radon at low exposure levels [69]. Nevertheless, despite radon being the most important risk factor for
LCINS, we could only include 2341 never-smoker lung cancer cases (in contrast to 9937 ever-smoker
cases) in this meta-analysis, highlighting the fact there is relatively little research carried out on this
subgroup of patients with lung cancer. This could be explained by: 1) LCINS being a relatively rare disease
compared with lung cancer in ever-smokers; and 2) general population statistics such as cancer registries
and death certificates mostly lack information on lifetime smoking histories, which makes it difficult to
identify eligible cases from population data.
By adhering to the methods specified in the PRISMA checklist, this study provided an objective
assessment of the risk of residential radon on lung cancer for never-smokers. To ensure that individual
studies were included only once for analysis, the pooled collaborative studies were prioritised given the
increased study power, which potentially allows both evaluation of effect modification [70] and more
reliable results [71]. As a result, four pooled collaborative studies which reported 24 case–control studies
and two individual studies (one case–control and one cohort) were included in the systematic review, and
among these studies, data from the four pooled collaborative studies were extracted for inclusion in the
meta-analysis. This provided the largest sample size to date for assessing the lung cancer risk of residential
radon exposure among never-smokers. All case–control studies in the included pooled collaborative studies
were adjusted for confounders, and this is also a strength of our results. In addition, our study provides
the estimated excess relative risk for ever-smokers and allows a comparison with that for never-smokers,
thereby evaluating a possible role of smoking as an effect modifier.
Of the four pooled studies, the greatest effect size (aERR 0.25) was observed in the Spanish pooled
study [52]. A possible explanation for this result is that the Spanish studies were conducted in more
radon-prone areas than the other pooled studies. Specifically, the Spanish study pooled four individual
studies conducted in northwest Spain (including Galicia) where radon is emitted at relatively high levels
due to the granitic nature of their soils [33], with about 25% of all homes in the area registering radon
concentrations ⩾148 Bq·m−3. When compared with a more recent pooled case–control study assessing the
relationship between residential radon exposure and lung cancer risk in the same regions and performed
by the same group [72], both results did not differ appreciably from each other, suggesting that in a given
radon-prone area, results on indoor radon and lung cancer risk would be consistent. Meanwhile, in the
North American pooled study [49] the highest radon concentrations (>7201 Bq·m−3) were detected in
Winnipeg [38, 49], but no increased risk of residential radon for LCINS was observed. Also, in the
Missouri-II study [45] where radon concentrations were higher than 148 Bq·m−3, contrasting results (with
and without statistically significant findings) were observed depending on the method of radon exposure
measurement [73]. Therefore, while radon-prone areas serve as one of the major factors in determining
the results, other factors like uncertainties of indoor radon exposure assessment and uncertainty of
equilibrium factor F due to geographical variations might also play an important role [24, 74]. The effects
of these uncertainties have been evaluated and it was shown that the errors could have led to an
underestimation of the reported ERR values [74]. Nevertheless, during the long study period (1960–2013)
of this meta-analysis, methods on radon detection and lung cancer diagnosis remain fairly consistent and
there is no evidence to suggest any significant discrepancy across this long study period [75, 76].
Previous studies have not established whether the effect of radon on lung cancer risk is different between
men and women. Studies based on both ever-smokers and never-smokers have produced inconsistent
results [47, 49, 51, 54]. Due to the overwhelming confounding effect of smoking, the effect of radon for
men and women separately should be assessed among never-smokers. As most never-smokers are
predominantly women and over 75% of the LCINS cases in our selected studies were women, there was
less precision in the estimates of risk from residential radon for male never-smokers. Also, while the
occupational miners’ studies included relatively large populations of men, the effects of radon exposure
within miners is not comparable to the effects of residential radon exposure in the general population.
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Despite these limitations, we found that the excess relative risk of LCINS in relation to residential radon
exposure was greater for men than women. As there is no strong evidence to suggest different
susceptibility to lung carcinogens by sex [17], further work is needed to elucidate potential differences
between male and female never-smokers, and whether they can be explained by other factors.
Historically, owing to the relatively high radon concentrations in underground mines, epidemiological
studies of occupational miners constituted an important and practical resource for research on
radon-induced lung cancer. The US National Research Council’s sixth committee on the Biological Effect
of Ionising Radiation (BEIR-VI) developed exposure–response risk models based on the analysis of data
from studies of occupational miners to estimate lung cancer risk associated with residential radon exposure
and to project the risk for individuals as well as for the entire US population [17]. To extend the risk
models from occupational miners to the general population, the committee adopted a set of assumptions
including a linear-non-threshold relationship between radon exposure and lung cancer risk for the
relatively low levels of residential radon exposures. Despite some initial controversies, the models are
generally accepted after their validation with case–control studies conducted at the population level [46,
48, 49]. It is also worth noting that miners with low radon exposure could experience similar radon
exposure to long-term residents with cumulative exposure to high radon concentrations in domestic
dwellings. Consequently, the downward extrapolation for lung cancer risks from occupationally exposed
miners to residentially exposed inhabitants conformed very closely to the observed aERRs from residential
radon studies. This was demonstrated in our results as our overall aERR of 0.11 (95% CI 0.06–0.17) per
100 Bq·m−3 was compatible with the excess odds ratio of 0.12 (95% CI 0.02–0.25) per 100 Bq·m−3 as
predicted by extrapolation from miner studies in the BEIR-VI report [17].
To assess the risk of radon exposure for the general population which includes both never- and
ever-smokers, it is important to understand the joint effects of tobacco smoke and radon because of the
overwhelming role of smoking as a causal factor for lung cancer. If the joint effects of smoking and radon
exposure are additive, then the absolute increase in lung cancer risk attributable to radon exposure is the
same in ever-smokers and never-smokers, and therefore proportionally less in ever-smokers, given they
have a much higher lung cancer risk than never-smokers. Whereas if the joint effects are multiplicative,
then the absolute increase in the lung cancer risk attributable to radon exposure is substantially greater for
smokers, and therefore the relative risks for radon exposure are the same in ever-smokers and
never-smokers [77]. Since there is evidence for a synergistic relationship between radon and smoking, it
implies “greater than additive” joint effects and is either a multiplicative joint association or
“sub-multiplicative” association (i.e. intermediate between additive and multiplicative) [17]. The BEIR-VI
committee applied both a full and a sub-multiplicative model, and it was found that a sub-multiplicative
model was more consistent with the available data. Our finding that the excess relative risks of radon were
greater in never-smokers than that in ever-smokers but not significantly different (p=0.32), implies there
was also consistency with a sub-multiplicative association, which is in line with the BEIR-VI report [17].
Despite evidence from cellular, molecular, epidemiological and animal studies providing some
understanding of the biological mechanisms involved in radon-induced lung cancer, the mechanism is still
not fully known. Radiation carcinogenesis is a complicated process and subject to the effects of different
environmental agents and genetic factors [78]. The carcinogenic effect induced by inhaled radon,
particularly to the bronchial epithelium and at bifurcation sites, is mainly through radon progenies, mostly
polonium 214 and 218, which emit high energy alpha particles as the predominant form of radiation [17].
Despite their limited capacity in tissue penetration, alpha particles can induce significant biological
damage in exposed tissues (due to their high relative biological effectiveness) through a variety of
cytogenetic effects. Some of these effects include gene mutations, chromosome aberrations, generation of
reactive oxygen species, modified cell cycles and increased production of proteins associated with cell-cycle
regulation and carcinogenesis [79]. There is also evidence suggesting that residential radon exposure could
play a role in the expression of epidermal growth factor receptor (EGFR) mutations and anaplastic
lymphoma kinase (ALK) translocations [80], and appears to increase the risk of small cell lung cancer
among all histological types [66, 81].
This study has several limitations. First, this systematic review is limited by exclusion of the grey literature
and conference proceedings, and thus the review may not contain all relevant articles. Also, though
requiring included studies to be published in peer reviewed journals provides a useful level of quality
control, it may potentially lead to publication bias. Nevertheless, we covered more publications than the
other similar systematic reviews on this topic and included a great number of LCINS cases from studies
conducted in different regions of the world and by different researchers, and this has reduced the
publication bias to a minimum degree. Secondly, despite efforts from the study investigators to standardise
exposure assessment, there remained potential measurement bias introduced by random uncertainties due
to the inaccuracy and discrepancy of the assessment of individual residential radon concentrations across
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the individual studies. Thirdly, because measures of heterogeneity for relevant effect estimates were not
reported in the pooled collaborative studies, we were unable to assess heterogeneity or examine potential
sources of heterogeneity in our meta-analysis.
These limitations notwithstanding, this meta-analysis has several strengths. First, this is the first
meta-analysis to provide a quantified risk estimate (aERR of 0.15 per 100 Bq·m−3 radon level) for the
association of residential radon exposure with lung cancer among never-smokers. Secondly, it includes the
most up-to-date data with the largest numbers of cases and controls from studies conducted in many parts
of the world (including both radon-prone and low-radon areas). Thirdly, the results conform well to the
risk assessment of radon exposure from BEIR-VI by extrapolating lung cancer risks from occupationally
exposed miners to residentially exposed inhabitants. Also, our results are in line with the BEIR-VI report
suggesting a sub-multiplicative model for the joint effects of radon exposure and tobacco smoke. In
addition, with the low ROB in the included studies, the precision of the point estimates of the effects of
radon and the consistency of the study results, there are good grounds for believing that the body of
evidence is in good strength.
This meta-analysis not only confirms the association between residential radon concentration and lung
cancer risk, but also quantifies the risk estimates for the association among never-smokers and
ever-smokers per 100 Bq·m−3 of radon exposure. Since the relative increase in risk for never-smokers is
not significantly different from the corresponding relative increase in risk for ever-smokers, it also provides
evidence for a synergistic interaction between radon and smoking. From a clinical perspective, when
never-smokers are diagnosed with lung cancer, radon should be considered as a potential cause, especially
in high-radon areas [82]. From a public health perspective, residential radon should be considered as an
important factor for predicting lung cancer risk in radon-prone areas [83], especially among ever-smokers
due to radon’s synergistic effect with tobacco smoke, and smoking cessation should be among their top
health priorities. Our findings also quantify the ERRs for never-smokers and ever-smokers at the World
Health Organization’s “action level of radon” of 100 Bq·m−3 [18] (environments and structures measuring
higher than the “action level” are advised to take remedial “action” to lower radon levels). This level
should be recommended rather than the level at 148 Bq·m−3 set by the United States Environmental
Protection Agency [19], or even the EU action level of 300 Bq·m−3 [84, 85]. In fact, among 157400 of lung
cancer deaths (for both ever-smokers and never-smokers) in the USA in 1995, at least 15400 were
attributable to radon [17]. Hence, it may be important to set a lower action level (from 148 to
100 Bq·m−3) as one part of an overall strategy to reduce the mortality rate. Nevertheless, for high-radon
areas, prompt remedial action should be taken to reduce further exposure to residents.
In conclusion, our meta-analysis demonstrated a significant association of residential radon exposure with
lung cancer as observed in never-smokers and ever-smokers with aERRs of 0.15 and 0.09 per 100 Bq·m−3
respectively, and there was evidence to support a synergistic effect of radon exposure with tobacco
smoking. Furthermore, lung cancer risk associated with residential radon may be greater for men than
women never-smokers, although the potential mechanisms underlying differences in risk by sex remain
TABLE 3 Important findings and impact on public health
Important findings Impact on public health
This is the first systematic review and meta-analysis
which provides quantified risk estimates for lung
cancer from residential radon exposure, with
aERRs of 0.15 and 0.09 per 100 Bq·m−3 among
never-smokers and ever-smokers respectively
These findings quantify the excess relative risks for
never-smokers and ever-smokers at the WHO
“action level of radon” of 100 Bq·m−3
There was evidence to support a synergistic
interaction between radon and tobacco smoking
Ever-smokers living in radon-prone areas should
be considered as a high-risk group and smoking
cessation should be among their top health
priorities
Among never-smokers, aERR of lung cancer per
100 Bq·m−3 of radon exposure was higher for men
than women
Among never-smokers in radon-prone areas, men
may need to take greater caution than women to
avoid or reduce their exposure to radon
aERR: adjusted excess relative risk; WHO: World Health Organization.
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unknown and represent a key area of future research. The public health impact of these findings is
summarised in table 3.
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